Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Invex Completes $900,000 Placement, Advances $10 Million Rekover Funding Plan

IXC: $0.100 +0.00% · MC: $8M

Invex Therapeutics issued shares to raise $900,000, completing the committed first tranche of its previously announced placement; the larger remaining tranche is still subject to shareholder approval, and the combined raise is intended principally to fund the planned Rekover study and ongoing Exenatide development. The quarter ended with $4 million in cash, down from $4 million in the prior quarter, while operating cash outflows eased to $425,000 from $501,000.

Source announcements: 2026-10-30 12:06 to 2026-10-30 14:56 Sydney time
Story updated 2026-10-30 14:58 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow ReportApplication for quotation of securities - IXCSection 708A Cleansing Notice
Comments